Amarin Corp Plcuk (AMRN) Cash from Investing Activities Growth (1y) (2011 - 2026)
Amarin Corp Plcuk (AMRN) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -38.43% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -38.14% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -46.27% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -388.99% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -46.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -50.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.54% |
| Mar 31, 2026 | -168.78% |
| Dec 31, 2025 | 84.61% |
| Sep 30, 2025 | 78.55% |
| Jun 30, 2025 | 164.32% |
| Mar 31, 2025 | -57.99% |
| Dec 31, 2024 | 67.83% |
| Sep 30, 2024 | -283.80% |
| Jun 30, 2024 | -86.32% |
| Mar 31, 2024 | 246.45% |
| Dec 31, 2023 | -155.22% |
| Sep 30, 2023 | -0.33% |
| Jun 30, 2023 | -53.11% |
| Mar 31, 2023 | -119.80% |
| Dec 31, 2022 | -211.20% |
| Sep 30, 2022 | 131.03% |
| Jun 30, 2022 | 44.50% |
| Mar 31, 2022 | -22.58% |
| Dec 31, 2021 | 5.62% |
| Sep 30, 2021 | -2,182.43% |